Advertisement
MBOT vs NVCR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBOT is a Hold and NVCR is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MBOT’s FA Score shows that 0 FA rating(s) are green whileNVCR’s FA Score has 1 green FA rating(s).
- MBOT’s FA Score: 0 green, 5 red.
- NVCR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MBOT’s TA Score shows that 5 TA indicator(s) are bullish while NVCR’s TA Score has 4 bullish TA indicator(s).
- MBOT’s TA Score: 5 bullish, 2 bearish.
- NVCR’s TA Score: 4 bullish, 6 bearish.
Price Growth
MBOT (@Pharmaceuticals: Other) experienced а -4.31% price change this week, while NVCR (@Medical/Nursing Services) price change was -3.54% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.05%. For the same industry, the average monthly price growth was -0.03%, and the average quarterly price growth was +8.63%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -4.89%. For the same industry, the average monthly price growth was -7.90%, and the average quarterly price growth was +10.70%.
Reported Earning Dates
MBOT is expected to report earnings on Feb 25, 2026.
NVCR is expected to report earnings on Feb 19, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-2.05% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-4.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| MBOT | NVCR | MBOT / NVCR | |
| Capitalization | 128M | 1.28B | 10% |
| EBITDA | -13.4M | -113.5M | 12% |
| Gain YTD | 70.536 | -61.544 | -115% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 0 | 642M | - |
| Total Cash | 32.7M | 1.03B | 3% |
| Total Debt | 149K | 798M | 0% |
MBOT | NVCR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 3 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 96 | |
PRICE GROWTH RATING 1..100 | 63 | 84 | |
P/E GROWTH RATING 1..100 | 100 | 8 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MBOT's Valuation (51) in the Biotechnology industry is somewhat better than the same rating for NVCR (100) in the Medical Specialties industry. This means that MBOT’s stock grew somewhat faster than NVCR’s over the last 12 months.
MBOT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NVCR (100) in the Medical Specialties industry. This means that MBOT’s stock grew similarly to NVCR’s over the last 12 months.
NVCR's SMR Rating (96) in the Medical Specialties industry is in the same range as MBOT (97) in the Biotechnology industry. This means that NVCR’s stock grew similarly to MBOT’s over the last 12 months.
MBOT's Price Growth Rating (63) in the Biotechnology industry is in the same range as NVCR (84) in the Medical Specialties industry. This means that MBOT’s stock grew similarly to NVCR’s over the last 12 months.
NVCR's P/E Growth Rating (8) in the Medical Specialties industry is significantly better than the same rating for MBOT (100) in the Biotechnology industry. This means that NVCR’s stock grew significantly faster than MBOT’s over the last 12 months.
| MBOT | NVCR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 65% |
| Stochastic ODDS (%) | 2 days ago 77% | 2 days ago 68% |
| Momentum ODDS (%) | N/A | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 81% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 85% |
| Advances ODDS (%) | 10 days ago 74% | 9 days ago 75% |
| Declines ODDS (%) | 2 days ago 83% | 3 days ago 90% |
| BollingerBands ODDS (%) | 7 days ago 83% | 2 days ago 66% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 86% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MBCYX | 25.50 | N/A | N/A |
| MassMutual Blue Chip Growth Svc | |||
| MAIRX | 10.45 | N/A | N/A |
| Victory Trivalent Intl Fd-Core Eq R6 | |||
| STEZX | 17.12 | N/A | N/A |
| AB International Strat Eqs Z | |||
| FDERX | 24.34 | -0.08 | -0.33% |
| Federated Hermes Strategic Div Gr R | |||
| LZFOX | 7.75 | -0.09 | -1.15% |
| Lazard Equity Franchise Open Shares | |||
MBOT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MBOT has been loosely correlated with POAI. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MBOT jumps, then POAI could also see price increases.
| Ticker / NAME | Correlation To MBOT | 1D Price Change % | ||
|---|---|---|---|---|
| MBOT | 100% | -4.50% | ||
| POAI - MBOT | 37% Loosely correlated | +3.81% | ||
| BNGO - MBOT | 34% Loosely correlated | -0.65% | ||
| CORBF - MBOT | 33% Loosely correlated | +46.67% | ||
| RCEL - MBOT | 33% Poorly correlated | +0.51% | ||
| OTCFF - MBOT | 32% Poorly correlated | +0.85% | ||
More | ||||
NVCR and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVCR has been loosely correlated with BLFS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if NVCR jumps, then BLFS could also see price increases.
| Ticker / NAME | Correlation To NVCR | 1D Price Change % | ||
|---|---|---|---|---|
| NVCR | 100% | +0.09% | ||
| BLFS - NVCR | 39% Loosely correlated | +1.54% | ||
| ALGN - NVCR | 38% Loosely correlated | +1.10% | ||
| AZTA - NVCR | 38% Loosely correlated | +2.07% | ||
| TWST - NVCR | 37% Loosely correlated | -2.12% | ||
| ENOV - NVCR | 36% Loosely correlated | -3.79% | ||
More | ||||